Halyard Health (NYSE: HYH) and Transenterix (NYSE:TRXC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitabiliy, analyst recommendations, valuation, institutional ownership, risk and dividends.


This table compares Halyard Health and Transenterix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Halyard Health 2.40% 8.16% 4.32%
Transenterix N/A N/A N/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Halyard Health and Transenterix, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halyard Health 0 3 1 0 2.25
Transenterix 0 0 1 0 3.00

Halyard Health currently has a consensus target price of $39.33, indicating a potential upside of 3.26%. Transenterix has a consensus target price of $2.75, indicating a potential upside of 463.52%. Given Transenterix’s stronger consensus rating and higher probable upside, analysts plainly believe Transenterix is more favorable than Halyard Health.

Institutional & Insider Ownership

91.9% of Halyard Health shares are held by institutional investors. 1.3% of Halyard Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Halyard Health and Transenterix’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Halyard Health $1.60 billion 1.11 $166.40 million $0.81 47.02
Transenterix $3.46 million 20.95 -$47.59 million N/A N/A

Halyard Health has higher revenue and earnings than Transenterix.


Halyard Health beats Transenterix on 7 of the 10 factors compared between the two stocks.

About Halyard Health

Halyard Health, Inc. is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections. The Company address healthcare needs, such as reducing the use of opioids, while helping patients move from surgery to recovery. The Medical Devices segment’s products include post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems and enteral feeding tubes. The S&IP segment includes product offerings, such as sterilization wrap, surgical drapes and gowns, facial protection, protective apparel and medical exam gloves.

About Transenterix

TransEnterix, Inc. is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera through eye movement. The system replicates laparoscopic motion and integrates three-dimensional high definition (3DHD) vision technology. The ALF-X System also offers responsible economics to hospitals by offering robotic technology with reusable instruments. The SurgiBot System is designed as a single-incision, patient-side robotic-assisted surgery system. The Company also develops and manufactures laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, and suction and irrigation instruments.

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.